4-氯-3H-咪唑并[4,5-c]吡啶-2-醇 | 54221-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 4-氯-3H-咪唑并[4,5-c]吡啶-2-醇
• 英文名称: 4-chloro-3H-imidazo[4,5-c]pyridin-2-ol
• 英文别名: 4-chloro-1,3-dihydroimidazo[4,5-c]pyridin-2-one
• CAS: 54221-73-7
• 化学式: C₆H₄ClN₃O
• mdl: MFCD11520892
• 分子量: 169.57
• InChiKey: KLECYJVFQWNFGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-氯-3H-咪唑并[4,5-c]吡啶-2-醇 、 对氟硝基苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 4-chloro-2-(4-nitro-phenoxy)-3H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  [DE] PHENYLHARNSTOFFDERIVATE ALS HEMMSTOFFE VON TYROSINKINASEN ZUR BEHANDLUNG VON TUMORERKRANKUNGEN
  [EN] PHENYLUREA DERIVATIVES USED AS INHIBITORS OF TYROSINKINASE FOR TREATING TUMORS
  [FR] DERIVES DE PHENYLUREE

  摘要：

  公式（I）中，R1a-R1e、R2a、R2b、R3和X具有权利要求1中所述的含义，是酪氨酸激酶，特别是TIE-2和Raf激酶的抑制剂，可用于治疗肿瘤等疾病。

  公开号：

  WO2006042599A1
• 作为产物：
  描述：

  4-nitro-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one 在 盐酸 作用下， 反应 12.0h， 以70%的产率得到4-氯-3H-咪唑并[4,5-c]吡啶-2-醇
  参考文献：
  名称：

  Synthesis and properties of 4-haloimidazo[4,5-c]pyridin-2-ones

  摘要：

  DOI：

  10.1007/bf01165030

文献信息

• Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20080214511A1

  公开（公告）日：2008-09-04

  The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , J, K, T, U, V, W, X, Y, Z, R 4 , R 5a , R 5b , R 5c , m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中A1，A2，B1，B2，B3，B4，D1，D2，J，K，T，U，V，W，X，Y，Z，R4，R5a，R5b，R5c，m和n在此定义），用作CGRP受体的拮抗剂，并用于治疗或预防CGRP参与的疾病，例如头痛、偏头痛和群集性头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Phenylurea Derivatives As Inhibitors Of Tyrosine Kinases For The Treatment Of Tumour Diseases
  申请人：Staehle Wolfgang

  公开号：US20080207682A1

  公开（公告）日：2008-08-28

  Compounds of the formula (I), in which R 1a -R 1e , R 2a , R 2b , R 3 and X have the meanings indicated in Claim 1 , are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.

  式(I)的化合物，其中R1a-R1e，R2a，R2b，R3和X的含义如权利要求1所示，是酪氨酸激酶，特别是TIE-2和Raf激酶的抑制剂，可用于治疗肿瘤等疾病。
• Spirolactam Bicyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090325991A1

  公开（公告）日：2009-12-31

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式：（其中变量A1、A2、A3、A4、A5、A6、A7、B、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• Spirolactam aryl cgrp receptor antagonists
  申请人：Bell Ian M.

  公开号：US20090247514A1

  公开（公告）日：2009-10-01

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化学式为I的化合物：（其中变量A1、A2、A3、A4、A5、A6、A7、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述）是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的疾病的方法。
• Bicyclic Anilide Spirolactam Cgrp Receptor Antagonists
  申请人：Bell M. Ian

  公开号：US20080096878A1

  公开（公告）日：2008-04-24

  The present invention is directed to compounds of Formula (I): (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及公式（I）的化合物：（其中变量A1、A2、B、J、K、m、n、R4、R5a、R5b和R5c的定义如本文所述），该化合物可用作CGRP受体拮抗剂，并可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。